Product Elements:
Sucralfate sucralfate sucralfate sucralfate d&c red no. 30 fd&c blue no. 1 aluminum lake magnesium stearate microcrystalline cellulose starch, corn light pink a56 oblong
Drug Interactions:
Drug interactions some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. however, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. the mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. in all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate el
Read more...iminated the interaction. because of the potential of sucralfate to alter the absorption of some drugs, sucralfate should be administered separately from other drugs when alterations in bioavailability are felt to be critical. in these cases, patients should be monitored appropriately.
Indications and Usage:
Indications and usage sucralfate tablets are indicated in: short-term treatment (up to 8 weeks) of active duodenal ulcer. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Dosage and Administration:
Dosage and administration active duodenal ulcer. the recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach. antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate. while healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. maintenance therapy: the recommended adult oral dosage is 1 g twice a day. elderly: in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see precautions geriatric use ). call your doctor for medical advice about side effects. you may report side effects to amneal pharmaceuticals at 1-877-835-5472 or fda at 1-800-fda-1088 or www
Read more....fda.gov/medwatch.
Contraindications:
Contraindications sucralfate tablets are contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
Adverse Reactions:
Adverse reactions adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. in studies involving over 2,700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). constipation was the most frequent complaint (2%). other adverse effects reported in less than 0.5% of the patients are listed below by body system: gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth dermatological: pruritus, rash nervous system: dizziness, insomnia, sleepiness, vertigo other: back pain, headache post-marketing cases of hypersensitivity have been reported with the use of sucralfate tablets, including dyspnea, lip swelling, pruritus, rash, and urticaria. cases of anaphylactic reactions, bronchospasm, laryngeal edema, edema of the mouth, pharyngeal edema, respiratory tract edema and swelling of the face have been reported with an unknown oral formulation of sucralfate. bezoar
Read more...s have been reported in patients treated with sucralfate. the majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings. inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli. sucralfate is not intended for intravenous administration. to report suspected adverse reactions, contact amneal pharmaceuticals at 1-877-835-5472 or fda at 1-800-fda-1088 or www.fda.gov/medwatch.
Drug Interactions:
Drug interactions some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. however, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. the mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. in all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate el
Read more...iminated the interaction. because of the potential of sucralfate to alter the absorption of some drugs, sucralfate should be administered separately from other drugs when alterations in bioavailability are felt to be critical. in these cases, patients should be monitored appropriately.
Use in Pregnancy:
Pregnancy teratogenic effects teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Pediatric Use:
Pediatric use safety and effectiveness in pediatric patients have not been established.
Overdosage:
Overdosage due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. sucralfate is only minimally absorbed from the gastrointestinal tract. risks associated with acute overdosage should, therefore, be minimal. in rare reports describing sucralfate overdose, most patients remained asymptomatic. those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.
Description:
Description sucralfate tablets, usp contain sucralfate, usp and sucralfate, usp is an α-d-glucopyranoside, β-d-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. tablets for oral administration contain 1 g of sucralfate, usp. also contain: d&c red #30 lake, fd&c blue #1 lake, magnesium stearate, microcrystalline cellulose, and starch. therapeutic category: antiulcer. structural formula
Clinical Pharmacology:
Clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. the small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. although the mechanism of sucralfateâs ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. the following observations also appear pertinent: studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site. in vitro , a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions. in human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%. in vitro , sucralfate adsorbs bile salts. these observations suggest that sucralfateâs antiulcer activity is the result of formation of an ulcer-adherent comple
Read more...x that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. there are approximately 14 to 16 meq of acid-neutralizing capacity per 1 g dose of sucralfate.
Carcinogenesis and Mutagenesis and Impairment of Fertility:
Carcinogenesis, mutagenesis, impairment of fertility chronic oral toxicity studies of 24 monthsâ duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose). there was no evidence of drug-related tumorigenicity. a reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. mutagenicity studies were not conducted.
How Supplied:
How supplied sucralfate tablets, usp 1 g are available as light pink, oblong tablets debossed with âa56â on one side and plain on the other side with a score line. they are supplied as follows: bottles of 100 with child-resistant closure: ndc 69238-1656-1 bottles of 500 with child-resistant closure: ndc 69238-1656-5 store at 20° to 25°c (68° to 77°f); excursions permitted between 15° to 30°c (59° to 86°f) [see usp controlled room temperature]. rx only distributed by: amneal pharmaceuticals llc bridgewater, nj 08807 rev. 05-2021-01 www.amneal.com
Package Label Principal Display Panel:
Principal display panel 100ct label